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PLoS One, in press: reference available tomorrow! 
What is MERS-CoV? 
•  Middle East respiratory syndrome 
coronavirus 
•  A betacoronavirus, related to severe 
acute respiratory syndrome (SARS-
CoV) and other coronaviruses 
•  Origin is likely bats? 
•  Camels a likely virus reservoir, or at 
least a liaison host 
•  In the Middle East MERS-CoV has 
zoonotic potential 
Middle East Respiratory Syndrome 
Coronavirus in Bats, Saudi Arabia. 
Memish et al, Emerg Infect Dis. 2013 
Nov; 19(11): 1819–1823.  
Camels as reservoir  
•  Several studies have found an epidemiological 
association between camels and human cases in the 
Middle East 
 
•  MERS-CoV antibody and virus have been detected in 
dromedary camels in the Arabian peninsula 
 
•  Similarity of MERS virus carried in humans and 
animals from Saudi Arabian patient who had contact 
with camels (Evidence for Camel-to-Human Transmission of MERS Coronavirus Esam I. Azhar, Ph.D., Sherif A. 
El-Kafrawy, Ph.D., Suha A. Farraj, M.Sc., Ahmed M. Hassan, M.Sc., Muneera S. Al-Saeed, B.Sc., Anwar M. Hashem, Ph.D., and Tariq A. Madani, 
M.D. N Engl J Med 2014; 370:2499-) 
 
Where is human MERS? 
http://coronamap.com/; 23 June 2015 
Where is camel MERS? 
West of Rift Valley 
(Turkana camels) 
camel density 
0.3-1.0  camels /km2 
East  of Rift Valley 
(Rendille & Somali 
camels) 
1.3-3.8 camels/km2 
 
n=774 samples 
collected 1992 - 2013 
Kenya? 
Corman VM et al. Antibodies 
against MERS coronavirus 
in dromedary camels, 
Kenya,1992–2013. Emerg 
Infect Dis. 2014.  
 Slide from Mario 
Younan) 
Our study site  
Cross-sectional study in Laikipia 
County in June-August 2013 
Serum collected from 335 camels 
in 9 herds, broadly representative 
of the Laikipia camel population 
 
Part of a wider camel health 
survey, incl demography, 
management, degree of isolation 
 
4-8ml blood sample collected from the 
jugular vein 
 
Transported on ice, centrifuged and serum 
separated and frozen at -20︎C 
 
Samples were shipped on dry ice for 
testing at Erasmus University, Netherlands: 
 
Serum samples tested at a 1:20 dilution for 
presence of IgG antibodies reacting with 
MERS-CoV, SARS and human coronavirus 
(HCoV) (Reusken et al) in a antigen 
microarray 
Results  
Prevalence  C.I  P value  
Adult >2 
Years 
61% (197) 54.2-68.3 0.09 
Juvenile 6- 
12 Months  
21% (71) 12.3-32.4 
<0.05 
Young <6 
months  
39% (57) 0 -98.7 
TOTAL  47% (335) 41.7-52.7 
No effect based on herd management type (p=0.1) 
and herd isolation (p=0.6) 
Conclusions 
High MERS-CoV exposure in camels provides support 
for the need of further research on the role of camels in 
the epidemiology of the disease 
 
High prevalence in the Laikipia herd, long term presence 
of virus in Kenya 
 
Exposure in animals that have been born and raised 
locally – local transmission of MERS-CoV 
 
No apparent animal health effects of these infections; no 
knowledge of when exposure occurred – but likely in 
young animals 
Recommendations 
Don’t panic! 
 
It seems probable that MERS-CoV is a widespread in Kenyan (?) 
camel populations, and has been for many years 
 
Effect on camels is similar to common cold 
 
To understand the zoonotic implications of this, we need to 
understand what the virus is in Kenya, and how it compares to 
others 
Therefore, placing virus diversity in a regional context is vital 
We need to isolate virus and undertake a genetic epidemiology study 
 
Further studies on the zoonotic implications should focus on MERS-
CoV exposure in humans (eg risk groups) with and without camel 
contact 
Next steps  
 
Design and implement a genetic epidemiology study 
Undertake a cross-sectional study of potential at-risk 
groups 
Establish routine MERS-CoV serology in Kenya 
Establish information exchange with stakeholders 
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